+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Toll Like Receptor"

Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Toll-Like Receptor 8 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-Like Receptor 8 Agonist - Pipeline Insight, 2024

  • Drug Pipelines
  • March 2024
  • 60 Pages
  • Global
From
Toll-Like Receptor Modulators - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-Like Receptor Modulators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Toll-like receptor 9 (TLR-9) Modulator - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-like receptor 9 (TLR-9) Modulator - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Toll-like receptor 4 antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-like receptor 4 antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Toll-like-receptor-agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-like-receptor-agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
TRS01 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

TRS01 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Ulcerative Colitis - Pipeline Insight, 2024 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Interleukin-33 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-33 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
EB05 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EB05 Emerging Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
Cobitolimod Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Cobitolimod Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020 - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 68 Pages
  • Global
From
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019 - Product Thumbnail Image

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 84 Pages
  • Global
From
From
From
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 118 Pages
  • Global
From
Loading Indicator

The Toll Like Receptor (TLR) market is a key component of drug discovery. TLRs are a family of proteins that recognize and respond to foreign molecules, such as bacteria and viruses. They play an important role in the body's immune system, helping to identify and respond to potential threats. TLRs are also involved in the development of autoimmune diseases, cancer, and other diseases. As such, they are a major target for drug discovery. TLR-based drug discovery is a rapidly growing field, with many companies investing in research and development. Companies are developing TLR-based therapies for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These therapies are designed to target specific TLRs, allowing for more targeted and effective treatments. Companies in the TLR market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more